Peptide eye drops derived from PEDF penetrated the cornea and reduced vascular leakage by 60%, cut inflammatory markers, and prevented retinal nerve cell death in diabetic mice with just once-weekly application.
~60% less leakageBoth PEDF peptide eye drops reduced diabetes-induced retinal vascular leakage by approximately 60% with once-weekly application
What the researchers found
Two PEDF-derived peptide eye drops (P60, antiangiogenic; P78, neuroprotective) penetrated through the cornea and reached the retina within 1-4 hours when applied topically to diabetic mice. Both peptides reduced vascular leakage by ~60% and restored tight junction proteins (ZO1 and occludin) to non-diabetic levels. The neuroprotective P78 peptide reduced inflammatory cytokines (9 of 20 measured, including TNF-α, IL-6, and IFN-γ), prevented microglia activation by ~60%, reduced retinal ganglion cell death by ~22%, and prevented inner retinal thinning by ~13%. These effects were achieved with just once-weekly eye drops for 15 weeks.
Why it matters
Diabetic retinopathy is the leading cause of blindness in working-age adults, and current treatments (laser therapy, injections into the eye) are invasive and burdensome. This study shows that peptide eye drops — applied just once a week — can penetrate to the retina and simultaneously address three major aspects of diabetic eye disease: vascular leakage, inflammation, and nerve cell death. If this works in humans, it could replace painful eye injections with simple drops.
How the study worked
Ins2(Akita) mice (a genetic model of type 1 diabetes) received PEDF peptide eye drops once weekly for 15 weeks starting at the onset of high blood sugar. Peptides were fluorescently labeled to track their penetration through the eye. Researchers measured vascular leakage, tight junction protein expression, inflammatory cytokine levels (20 cytokines), microglia activation, retinal ganglion cell survival, and retinal layer thickness. Signaling pathways (ERK1/2, AKT) were analyzed in Müller glial cells.
Who was studied
Ins2(Akita) diabetic mice treated with peptide eye drops for 15 weeks
What this study cannot tell us
This was an animal study in a genetic mouse model of diabetes, which may not perfectly replicate human diabetic retinopathy. The once-weekly dosing achieved moderate vitreous concentrations, and optimal dosing for humans is unknown. Only type 1 diabetic mice were studied. Long-term safety of repeated topical peptide application wasn't assessed beyond 15 weeks.
How to read the evidence
This is a preclinical study in a genetic mouse model of diabetes. The results are robust with multiple outcome measures, but no human clinical data exists yet.
When this study was published
Published in 2012. PEDF peptide eye drops for diabetic retinopathy have continued to be researched, but have not yet reached human clinical trials as of the latest available data.
The bigger picture
Current diabetic retinopathy treatments — anti-VEGF injections directly into the eye — are effective but dreaded by patients and require frequent clinic visits. The idea that a peptide eye drop could replace injections while addressing not just leaking vessels but also inflammation and nerve damage is transformative. PEDF peptides target the disease from multiple angles simultaneously, which is unusual for any single treatment approach.
Questions still open
- Can PEDF peptide eye drops achieve sufficient retinal concentrations in human eyes, which are much larger than mouse eyes?
- Would combining the antiangiogenic P60 and neuroprotective P78 peptides produce additive benefits?
- How would once-weekly peptide drops compare to monthly anti-VEGF injections in a head-to-head study?
Common questions
Could eye drops really replace eye injections for diabetic retinopathy?
What is PEDF and why is it important for the eyes?
Read the original research
Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice.
Molecular medicine (Cambridge, Mass.), 18(1), 1387-401
Citation
Liu, Yanling; Leo, Lan Franco; McGregor, Corban; Grivitishvili, Anzor; Barnstable, Colin J; Tombran-Tink, Joyce. (2012). Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice.. Molecular medicine (Cambridge, Mass.), 18(1), 1387-401. https://doi.org/10.2119/molmed.2012.00008